In tumors with low SLFN11 expression, such as ovarian cancer, breast cancer, colorectal cancer, small - cell lung cancer, and bladder cancer, combine chemotherapy with HDAC inhibitors or demethylating agents to verify whether they can enhance chemotherapy sensitivity by upregulating SLFN11. Here, HDAC9 is linked to urinary bladder carcinoma.